MX2009013008A - Vacunas para la influenza. - Google Patents

Vacunas para la influenza.

Info

Publication number
MX2009013008A
MX2009013008A MX2009013008A MX2009013008A MX2009013008A MX 2009013008 A MX2009013008 A MX 2009013008A MX 2009013008 A MX2009013008 A MX 2009013008A MX 2009013008 A MX2009013008 A MX 2009013008A MX 2009013008 A MX2009013008 A MX 2009013008A
Authority
MX
Mexico
Prior art keywords
denmark
dna
influenza
strain
pandemic
Prior art date
Application number
MX2009013008A
Other languages
English (en)
Inventor
Anders Formsgaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MX2009013008A publication Critical patent/MX2009013008A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a vacunas y también describe el uso de la molécula ADN y/o ARN desnudo que codifica la hemaglutinina (HA) de la influenza pandémica, por ejemplo el virus de la influenza A H1N1 de 1918 y/o H2N2 de 1957 y/o H3N2 DE 1968 y/o la cepa ATV pandémica de ave patogénica alta (A/zopilote/Dinamarca/6370/06(H5N 1) y/o cepa del virus de la influenza aviar (ATV) patogénica baja H5N7 de 2001 (A/Ánade/Dinamarca/64650/03(H5N7)) o la cepa AIV potogénica alta H5N1 de Dinamarca en marzo de 2006 (A/zopilote/Dinamarca/6370/06(H5N1) o en 2008 (A/pato/Dinamarca/53-147-8/08 (H7N1) o en 2004 (A/pato mediano /Dinamarca/66174G18/04 (H2N3) como un componente de vacuna contra las infecciones actuales y próximas de influenza A que contienen H1,H2,H3,H5,H7, N1,N2,N3 en humanos y en cerdos opcionalmente con la molécula de ADN y/o ARN desnudo que codifica la neuraminidasa (NA) y/o proteína de matriz (M) y/o la nucleoproteína (NP) del virus de la influenza pandémico incluido. Si los componente de la vacuna se usan como vacunas de ADN o ARN con o sin la proteína correspondiente, los codones pueden opcionalmente "humanizarse" usando codones preferidos de los genes mamíferos altamente expresados y la administración de esta vacuna de ADN puede ser por inyección de solución salina o solución amortiguadora salina de ADN o ARN Desnudo o inyección de plasmo de ADN o gen lineal que expresa fragmentos de ADN acoplados a las partículas. La adición de la proteína de matriz (M) y/o la nucleoproteína (NP) como proteína o ADN de la cepa de la influenza de 1918.
MX2009013008A 2007-05-31 2008-05-30 Vacunas para la influenza. MX2009013008A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700784 2007-05-31
US93411707P 2007-06-11 2007-06-11
PCT/DK2008/000201 WO2008145129A2 (en) 2007-05-31 2008-05-30 Influenza vaccines

Publications (1)

Publication Number Publication Date
MX2009013008A true MX2009013008A (es) 2010-06-09

Family

ID=39217966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013008A MX2009013008A (es) 2007-05-31 2008-05-30 Vacunas para la influenza.

Country Status (4)

Country Link
US (2) US20080299151A1 (es)
EP (2) EP3040082A1 (es)
MX (1) MX2009013008A (es)
WO (1) WO2008145129A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130031A1 (en) 2015-02-10 2016-08-18 Instytut Biochemii I Biofizyki Pan Dna vaccine against h5n1 influenza virus, modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
PL2358386T3 (pl) * 2008-11-28 2017-04-28 Statens Serum Institut Zoptymalizowane szczepionki na grypę
SG10201403557QA (en) 2009-06-25 2014-10-30 Medimmune Llc Swine influenza hemagglutinin variants
US20110159031A1 (en) * 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
AU2013201928B2 (en) * 2010-01-26 2015-03-19 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
US8298820B2 (en) * 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
AU2015202267B2 (en) * 2010-01-26 2017-03-23 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
EP2616545B1 (en) 2010-09-14 2018-08-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
CN102251060A (zh) * 2011-08-03 2011-11-23 中国人民解放军军事医学科学院放射与辐射医学研究所 A型流感病毒流行毒株耐药检测基因芯片的制备和使用方法
PL220281B1 (pl) 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
EP2758038B1 (en) * 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Novel influenza hemagglutinin protein-based vaccines
AU2012347878B2 (en) 2011-12-05 2018-05-10 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
CN102433391B (zh) * 2011-12-06 2013-08-21 深圳市普瑞康生物技术有限公司 一种甲型流感病毒甄别与耐药检测基因芯片的制备和用途
RU2653756C2 (ru) * 2012-02-07 2018-05-14 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
CN105209071A (zh) * 2013-03-14 2015-12-30 抗非特公司 用于提高疗效的基于鼻内递送中和抗体的组合物和方法
BR112016007868A2 (pt) 2013-10-11 2017-12-05 Us Health vacinas contra o vírus de epstein-barr
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
LT3134131T (lt) 2014-04-23 2022-02-10 Modernatx, Inc. Nukleorūgšties vakcinos
CA2974346A1 (en) 2014-12-31 2016-07-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Novel multivalent nanoparticle-based vaccines
AU2017321883B2 (en) 2016-09-02 2022-07-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
CN107753943A (zh) * 2017-09-30 2018-03-06 华南农业大学 一种h7亚型禽流感dna疫苗及其制备方法
CN111526886A (zh) * 2017-10-27 2020-08-11 国家血清研究所 多基因流感疫苗
AU2022343710A1 (en) * 2021-09-07 2024-04-18 The Trustees Of The University Of Pennsylvania Universal influenza vaccine and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
US20020165176A1 (en) * 2000-05-01 2002-11-07 Haynes Joel R. Nucleic acid immunization
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
AU2005248361B2 (en) * 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
BRPI0518728A2 (pt) 2004-12-09 2008-12-02 Univ Pittsburgh vacinas para a resposta rÁpida À pandemia de gripe aviÁria
EP2402023A1 (en) * 2006-06-28 2012-01-04 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016130031A1 (en) 2015-02-10 2016-08-18 Instytut Biochemii I Biofizyki Pan Dna vaccine against h5n1 influenza virus, modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing

Also Published As

Publication number Publication date
WO2008145129A2 (en) 2008-12-04
EP3040082A1 (en) 2016-07-06
US20080299151A1 (en) 2008-12-04
WO2008145129A3 (en) 2009-05-28
US20100160421A1 (en) 2010-06-24
US8288090B2 (en) 2012-10-16
EP2160198A2 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
MX2009013008A (es) Vacunas para la influenza.
Watanabe et al. The changing nature of avian influenza A virus (H5N1)
Mair et al. Receptor binding and pH stability—How influenza A virus hemagglutinin affects host-specific virus infection
Russell Hemagglutinin stability and its impact on influenza A virus infectivity, pathogenicity, and transmissibility in avians, mice, swine, seals, ferrets, and humans
Neumann et al. Host range restriction and pathogenicity in the context of influenza pandemic
Bouvier et al. The biology of influenza viruses
Neumann et al. Emergence and pandemic potential of swine-origin H1N1 influenza virus
Sakoda et al. Characterization of H5N1 highly pathogenic avian influenza virus strains isolated from migratory waterfowl in Mongolia on the way back from the southern Asia to their northern territory
WO2010077986A3 (en) Production of influenza vaccines
RU2013135498A (ru) Экспрессионные системы
HRP20130163T1 (hr) Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
Donatelli et al. Human–animal interface: the case for influenza interspecies transmission
KováčOVá et al. Sequence similarities and evolutionary relationships of influenza virus A hemagglutinins
Kim et al. Avian influenza A viruses: evolution and zoonotic infection
JP2009511080A5 (es)
WO2010060430A3 (en) Optimized influenza vaccines
Li et al. T-cell-mediated cross-strain protective immunity elicited by prime–boost vaccination with a live attenuated influenza vaccine
Neumann H5N1 influenza virulence, pathogenicity and transmissibility: what do we know?
WO2012082803A3 (en) Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof
Shichinohe et al. Selection of H3 avian influenza viruses with SAα2, 6Gal receptor specificity in pigs
EA201300525A1 (ru) Новые вакцины против пандемичного вируса гриппа a/h1n1
MX2022012251A (es) Vacuna universal contra la influenza usando arnm modificado con nucleósidos.
Ameghi et al. Protective immunity against homologous and heterologous influenza virus lethal challenge by immunization with new recombinant chimeric HA2-M2e fusion protein in balb/c mice
Wiriyarat et al. Erythrocyte binding preference of 16 subtypes of low pathogenic avian influenza and 2009 pandemic influenza A (H1N1) viruses
Su et al. Emergence and pandemic potential of avian influenza a (H7N9) virus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal